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Summary
Background Bullous pemphigoid (BP) is an autoimmune blistering skin disorder
associated with significant morbidity and mortality. Doxycycline and pred-
nisolone to treat bullous pemphigoid were compared within a randomized con-
trolled trial (RCT).
Objectives To compare the cost-effectiveness of doxycycline-initiated and pred-
nisolone-initiated treatment for patients with BP.
Methods Quality-of-life (EuroQoL-5D-3L) and resource data were collected as part
of the BLISTER trial: a multicentre, parallel-group, investigator-blinded RCT.
Within-trial analysis was performed using bivariate regression of costs and qual-
ity-adjusted life-years (QALYs), with multiple imputation of missing data,
informing a probabilistic assessment of incremental treatment cost-effectiveness
from a health service perspective.
Results In the base case, there was no robust difference in costs or QALYs per
patient at 1 year comparing doxycycline- with prednisolone-initiated therapy
[net cost £959, 95% confidence interval (CI) £24 to £1941; net QALYs
0024, 95% CI 0088 to 0041]. However, the findings varied by baseline
blister severity. For patients with mild or moderate blistering (≤ 30 blisters) net
costs and outcomes were similar. For patients with severe blistering (> 30 blis-
ters) net costs were higher (£2558, 95% CI £82 to £5198) and quality of life
poorer (0090 QALYs, 95% CI 022 to 0042) for patients starting on doxy-
cycline. The probability that doxycycline would be cost-effective for those with
severe pemphigoid was 15% at a willingness to pay of £20 000 per QALY.
Conclusions Consistently with the clinical findings of the BLISTER trial, patients
with mild or moderate blistering should receive treatment guided by the safety
and effectiveness of the drugs and patient preference – neither strategy is clearly
a preferred use of National Health Service resources. However, prednisolone-
initiated treatment may be more cost-effective for patients with severe blistering.
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What’s already known about this topic?
• Bullous pemphigoid is a subepidermal blistering autoimmune skin disease, associ-
ated with increased morbidity and mortality.
• Prednisolone has long been the main systemic treatment. Although tetracyclines
have also been used, their effectiveness and safety have not been estimated reliably
to date.
• BLISTER was a pragmatic noninferiority randomized controlled trial starting oral
treatment with either doxycycline 200 mg daily or prednisolone 0.5 mg kg1 per
day.
• That trial demonstrated that doxycycline was a significantly safer treatment than
prednisolone but less effective in terms of blister control at 6 weeks.
What does this study add?
• Although doxycycline and prednisolone offered different effectiveness and safety
profiles, costs and quality of life were similar when comparing patients presenting
with mild-to-moderate blistering (≤ 30 blisters).
• For patients with severe blistering (> 30 blisters) at presentation, starting pred-
nisolone resulted in lower cost and higher quality of life, making it a more cost-
effective strategy.
Bullous pemphigoid (BP) is an autoimmune skin disease char-
acterized by intense itching, erythema, blisters and possible
secondary infection.1 The incidence of BP ranges between 14
and 42 new patients per million in Europe, doubling in the
last decade.2,3 BP is more common in patients over 70 years
of age, and is associated with increased morbidity and mortal-
ity.2,4,5 Although oral prednisolone has been the basis of treat-
ment for over 50 years,4,6 significant adverse effects in older
patients and uncertainty as to optimal dosing are problematic.
Whole-body long-term topical use of superpotent topical cor-
ticosteroids may be as effective as high-dose oral pred-
nisolone, with lower risk of harm, although this may not be
suitable for those with limited mobility or in care.3,7,8 Tetra-
cyclines have been used in BP for their anti-inflammatory
action,9,10 although with little supporting evidence.11 While
tetracyclines might be less effective, they are expected to be
safer than oral prednisolone.
The Bullous Pemphigoid Steroids and Tetracyclines (BLIS-
TER) trial was designed to provide a pragmatic, definitive
comparison of starting treatment with the tetracycline doxycy-
cline (200 mg per day) or starting treatment with oral pred-
nisolone (05 mg kg1 per day).12,13 Thus, BLISTER was
designed to detect whether an acceptable level of short-term
blister control could be achieved with a strategy of starting
treatment with doxycycline (noninferiority), while providing
increased long-term safety when compared with prednisolone.
In brief, BLISTER was a multicentre, parallel-group, investi-
gator-blind randomized controlled trial, comparing doxycy-
cline and prednisolone-initiated treatment, recruiting 253
adult patients from 54 U.K. and seven German dermatology
centres, with a primary efficacy outcome at 6 weeks and a
long-term safety outcome at 52 weeks. Patients were also
assessed at 13, 26 and 39 weeks.14 The mean age of partici-
pants was 78  10 years, 29% had severe blistering and the
groups were similar at baseline. Patients were allowed to
switch treatments or alter the dose of prednisolone after the
first 6 weeks in order to reflect real-world clinical practice.
Topical corticosteroids were allowed in small quantities
(< 30 g per week to localized areas for symptomatic relief
only) for the first 3 weeks and after 6 weeks.
The noninferiority primary effectiveness outcome was met
(the proportion of participants with at most three blisters at
6 weeks): doxycycline 74% vs. prednisolone 91%, an
adjusted difference of 19% (90% confidence interval 11–
26%) favouring prednisolone. The upper-bound 90%
confidence interval of 26% was well within the prespecified
margin of noninferiority of 37%. For the safety analysis,
treatment-related severe, life-threatening and fatal events over
1 year occurred in 18% of the doxycycline group vs. 36%
with prednisolone, an adjusted difference of 19% (95% confi-
dence interval 8–30%). This is clear evidence of increased
safety for a treatment strategy of starting with doxycycline.
The clinical study found no evidence of interaction between
treatment effectiveness and safety according to the severity of
disease at baseline (i.e. number of blisters), with severity
classified as mild (three to nine blisters), moderate (10–30)
or severe (> 30).
Economic analysis informs decision makers about the value
for money of treatment alternatives, as healthcare resources
are limited and prioritization should consider the efficient use
of resources.15 An economic analysis was conducted as an
integral part of the BLISTER study, following a prospective
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analysis plan, in order to provide robust evidence of cost-
effectiveness to inform health service decision making.
Patients and methods
A within-trial patient-level cost-effectiveness analysis was
undertaken comparing doxycycline- and prednisolone-initiated
treatment in patients with BP, using data from the BLISTER
trial. To quantify the likelihood that either intervention is
cost-effective, the effect of treatment changes was estimated as
cost and quality-adjusted life-years (QALYs);16 the analysis
was from the U.K. National Health Service (NHS) perspective.
As follow-up was limited to 1 year, no discounting of costs
and benefits was applied. The analysis followed intention-to-
treat principles, in which patients were included in the analy-
sis according to the treatment allocated by randomization, and
irrespectively of subsequent care.
Outcomes
Generic health-related quality of life was assessed using the
EuroQoL questionnaire, a patient-completed two-page ques-
tionnaire consisting of the EQ-5D-3L descriptive system and
the EQ visual analogue scale (EQ-VAS).17,18 The EQ-5D-3L
includes five questions addressing mobility, self-care, usual
activities, pain/discomfort and anxiety/depression, with each
dimension assessed at three levels: no problems, some prob-
lems and extreme problems. EQ-5D scores were converted to
health status scores using the U.K. time-trade-off value set rec-
ommended by the EuroQoL group,19 providing a single
health-related index including 0 (death) and 1 (perfect
health), where negative scores are possible for some health
states. Patients who died during the study were subsequently
scored zero at later scheduled follow-up visits for both cost
and EQ-5D score and are included as observed data.
The EQ-VAS reports self-rated health on a vertical, visual
analogue scale where 100 denotes ‘best imaginable health
state’ and 0 denotes ‘worst imaginable health state’. Addition-
ally, the Dermatology Life Quality Index (DLQI) was recorded
as a disease-specific measure. The DLQI asks patients 10 ques-
tions about how their skin condition has affected their life
over the past week, providing an aggregate score in the range
0–30.20 Quality-of-life measures were captured during clinic
visits at baseline and 6, 13, 26, 39 and 52 weeks.
Using the trapezoidal rule, the area under the curve (AUC)
of health status scores was calculated, providing patient-level
QALY estimates for the cost-effectiveness analysis.21 Similarly,
EQ-VAS and DLQI scores were integrated discretely over time.
As AUC estimates were predicted to correlate with baseline
scores (and thus potential baseline imbalances), AUC estimates
were adjusted for baseline scores.22
Resource use and cost
Resource assessments occurred at scheduled clinic visits. Use
by patients of study and nonstudy drugs was recorded in the
trial drug log. BP-related health service contacts were recorded
during clinic visits using patient diaries as an aide-memoire.
At clinic visits, all health service resource use was recorded,
together with attribution of resources to BP. Patients with no
recorded resource use were excluded from the analysis.
Patient costs were estimated in U.K. pounds sterling (2013)
as the sum of resources used weighted by their reference
costs. Study drugs were prescribed at varying doses and dura-
tions. Using national Prescription Cost Analysis (PCA) data,23
average costs per unit weight of therapeutic agent were deter-
mined and applied to patient drug use records: doxycycline
£00015 per mg and prednisolone £00221 per mg. Use of
topical steroids was costed similarly using PCA data.
Costs of inpatient stays (in days) and outpatient visits were
estimated using Hospital Episodes Statistics (HES) and the
National Schedule of Reference Costs.24,25 National HES data
were explored for inpatient episodes with a primary diagnosis
of L120 bullous pemphigoid; the 10 most common Health-
care Resource Group HRG4+ codes associated with that diag-
nosis were included, accounting for 962% of admissions.
Daily costs for each code were estimated from NHS reference
costs, and a volume-weighted average cost per admission for
BP was estimated allowing for mean stay and cost per day.26
Inpatient stays cost £334 per day and outpatient attendances
were £98 per visit. General practitioner (GP) clinic and home
visits, and practice and district nurse visits were costed using
unit costs provided by the Personal Social Services Research
Unit:27 community care contacts were GP (clinic) £46, GP
(home) £92, practice nurse £13 and district nurse £39.
Analysis
Follow-up of elderly patients with BP within trials is problem-
atic, and some incompleteness of data was anticipated. Conse-
quently, a base-case analysis was constructed whereby missing
data were imputed using multiple imputation. The base-case
analysis included the imputed within-trial incremental cost
and QALYs gained, adjusted for trial baseline covariates and
including use of resources attributed to BP. Supportive sensi-
tivity analyses included only patients with complete data,
exploring the impact of imputation, and estimation including
all resources recorded regardless of attribution.
The base-case analysis used multiple imputation, conducted
according to good practice guidance.28,29 Multiple imputation
provides unbiased estimates of treatment effect if data are
missing at random; this assumption was explored in the data,
for example by using logistic regression for missing costs and
QALYs against baseline variables.30 A regression model was
used to generate multiple imputed datasets (or ‘draws’) for
individual treatment groups, where missing values were pre-
dicted drawing on predictive covariates: age, sex, baseline
blister severity and baseline Karnofsky score. Outcome mea-
sures (at each time point) and costs contributed as both pre-
dictors and imputed variables.
Each draw provided a complete dataset, which reflected the
distributions and correlations between variables. Predictive
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mean matching drawn from the five nearest neighbours
(knn = 5) was used to enhance the plausibility and robustness
of imputed values, as normality could not be assumed. The
imputation model used fully conditional (Markov chain Monte
Carlo) methods (multiple imputation by chained equations),
which are appropriate when missing and correlated data occur
in more than one variable. Each draw was analysed indepen-
dently using bivariate regression (see below) and the estimates
obtained were pooled to generate mean and variance estimates
of costs and QALYs using Rubin’s rule – a method that cap-
tures within and between variances for imputed samples.31 To
minimize the information loss of finite imputation sampling,
50 draws were taken, resulting in a loss of efficiency relative
to infinite sampling of < 05% in all imputed values. The dis-
tribution of imputed and observed values was compared visu-
ally and statistically to establish that imputation did not
introduce bias into subsequent estimation.
Bivariate regression using seemingly unrelated regression
equations was used to model incremental changes in costs and
QALYs. This method respects the correlation of costs and out-
comes within the data, and allows adjustment for a set of
covariates, which can be explored and which improve preci-
sion.32 Baseline quality-of-life scores were included within all
models to allow for potential baseline imbalances.19 Joint dis-
tributions of costs and outcomes were generated using the
(nonparametric) bootstrap method, with replicates used to
populate a cost-effectiveness plane. Bootstrapping jointly
resamples costs and outcomes from the original data with
replacement (maintaining the sample correlation structure) to
create a new bootstrap sample from which changes in costs
and QALYs are estimated. Using bias-corrected nonparametric
bootstrapping, 5000 bootstraps were taken per model or draw
evaluated. Mean estimates are reported with 95% credible
intervals (CIs).
The incremental cost-effectiveness ratio (ICER) was esti-
mated as the difference between treatments in mean total costs
divided by the difference in mean total QALYs. Value for
money is determined by comparing the ICER with a threshold
value, typically the National Institute for Health and Care
Excellence threshold for British studies, of £20 000–£30 000
per QALY.33 This represents the willingness to pay for an
additional QALY, and lower values than the threshold could
be considered cost-effective for use in the NHS. Base-case
assumptions are explored using a range of supportive sensitiv-
ity analyses.
The net monetary benefit (NMB) of changing treatment
was reported as a recalculation of the ICER at a range of
thresholds of willingness to pay for an additional QALY. The
NMB succinctly describes the resource gain (or loss) when
investing in a new treatment when resources can be used else-
where at the same threshold. NMB estimates were used to
generate cost-effectiveness acceptability curves (CEACs). The
CEAC compares the likelihood that treatments are cost-effec-
tive as the willingness-to-pay threshold varies.30
The expected value of perfect information (EVPI) is the
upper limit of the value to a healthcare system of further
research to eliminate uncertainty.34 Findings from cost-effec-
tiveness analyses remain uncertain because of the imperfect
information they use. If a wrong adoption decision (to make
a treatment available) is made this will bring with it costs in
terms of health benefit forgone; the NMB framework allows
this expected cost of uncertainty to be determined and guide
whether further research should be conducted to eliminate
uncertainty.
Analyses and modelling were undertaken in STATA 14 SE
(STATACORP, College Station, TX, U.S.A.). Reporting follows the
Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) statement.35
Results
Completeness of data
Of 253 patients within the clinical trial, 220 (87%) were
included in the economic analysis (Table 1). Included and
excluded patients were similar in treatment allocation, age,
sex, Karnofsky score and blister severity. Of these 220
patients, 164 (75%) had complete EQ-5D assessments for all
periods. There was a pattern of decreasing completeness as
follow-up proceeded. Resource data were complete for 191
patients (87%). It was not possible to explore completeness of
healthcare costs by follow-up visit as patients could use diaries
to complete missing data at a later follow-up visit and the
study drug report covered the entire follow-up period. When
considering both utilities and resource use, complete informa-
tion was available for 143 patients (65%). Completeness of
data was similar when comparing treatment arms (Table 1).
Thirty-three patients died during the trial period, 14 (125%)
in the doxycycline-initiated arm and 19 (176%) in the pred-
nisolone-initiated arm, predominantly due to the age and
Table 1 Completeness of data by follow-up visit
Prednisolone,
n = 108
Doxycycline,
n = 112
Total,
n = 220
Health status (EQ-5D)a
Baseline 107 (991) 112 (1000) 219 (995)
6 weeks 102 (944) 108 (964) 210 (955)
13 weeks 101 (935) 101 (902) 202 (918)
26 weeks 96 (889) 93 (830) 189 (859)
39 weeks 94 (870) 90 (804) 184 (836)
52 weeks 92 (852) 90 (804) 182 (827)
All visits 83 (769) 81 (723) 164 (745)
Resource use
Drug use 95 (880) 102 (911) 197 (895)
Health service
contacts
103 (954) 107 (955) 210 (955)
Cost 92 (852) 99 (884) 191 (868)
Health status and
resource use
Cost and EQ-5D 72 (667) 71 (634) 143 (650)
All values are n (%). aEuroQoL-5D-3L index score.
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comorbidities of patients. Missing values were imputed to
provide a base-case analysis including all 220 patients.
Complete-case estimates
Mean EQ-5D scores, resource use and cost data are reported
by treatment in Table S1 (see Supporting Information). Over
the 52-week follow-up period there were no significant differ-
ences in QALYs when comparing the two treatment strategies.
Although resource use comparisons (attributed to BP) were
generally not significant, there was a pattern of greater care
received by patients on doxycycline, consistent with a lower
level of clinical effectiveness reflected (by design) in the pri-
mary outcome. There was significant, subsequent crossover to
the alternative study drug in patients with poor outcomes. Of
patients starting on prednisolone, 126% subsequently received
at least one prescription of doxycycline; of patients starting on
doxycycline, 578% subsequently received at least one pre-
scription of prednisolone.
Four different types of potent to very potent topical corti-
costeroids were commonly used; the overall use of any topical
corticosteroid during the trial was very similar for patients ini-
tiating on prednisolone (768%) and doxycycline (725%).
However, the amount used (and steroid potency) was notably
lower in the prednisolone group (average prescribed amount
of all topical steroids among users: prednisolone 121 g vs.
doxycycline 277 g). Similar proportions of patients received
the immunosuppressant azathioprine (prednisolone 42% vs.
doxycycline 88%), although again the amount used was far
lower in the prednisolone group (average prescribed amount
among users: prednisolone group 29 g vs. doxycycline group
124 g). Patterns of resource use were costed using national
reference values (see Methods: Resource use and cost).
Although costs for patients starting on doxycycline treatment
appeared greater over 1 year, the increase was imprecise.
Cost-effectiveness analysis
The joint distribution of incremental cost and outcome for the
base-case analysis is shown graphically in Figure 1. Patients
started on doxycycline (compared with prednisolone) experi-
enced a slightly lower average quality of life (0024 QALYs,
95% CI  0088 to 0041), while tending to incur higher aver-
age health costs (£959, 95% CI –£24 to £1941) compared with
those started on prednisolone, although neither finding was sig-
nificant (Table S2; see Supporting Information). These findings
are consistent with the results of the clinical trial, which demon-
strated a compromise between reduced effectiveness and
increased safety for doxycycline. The joint distribution of cost
and outcome is summarized within the NMB metric. Using a
willingness-to-pay criterion of < £20 000 per QALY gained, the
NMB associated with doxycycline-initiated therapy was negative
(£1432; 95% CI £3094 to £230). Thus, the base-case analy-
sis suggests that NHS resources would be better directed to
prednisolone- than doxycycline-initiated therapy in terms of
cost-effectiveness. This finding is echoed in the cost-effective-
ness acceptability curve, which expresses the NMB finding as a
probability (Fig. 2; all patients). The likelihood that doxycy-
cline-initiated treatment is cost-effective is 46% given a willing-
ness-to-pay criterion of < £20 000 per QALY gained (Table S2;
see Supporting Information). Note that one-sided model proba-
bilities should not be compared with inferential findings from
(two-sided) statistical tests.
Sensitivity analyses
Comparing mean costs and QALY estimates using different
modelling assumptions supports the base-case finding
(Table S2; see Supporting Information). The qualitative simi-
larity of NMB estimates comparing imputed and complete-
case analysis, covariate adjustment and range of costs included
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Fig 1. Cost-effectiveness plane: doxycycline compared with prednisolone, base-case analysis. Cost per quality-adjusted life-year (QALY), £, 2013.
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supports the validity of the imputation process and assump-
tions.
Subgroup analyses
There was no interaction between treatment effect and trial
stratifying variables, except in the case of disease severity. The
63 patients (286%) recruited with severe blistering (> 30
blisters at baseline) demonstrated a different cost and outcome
pattern from patients with mild or moderate disease, as shown
in Table S2 (see Supporting Information) and Figure 3. For
patients presenting with mild or moderate disease, the differ-
ences in costs and QALYs are very small and thus the costs
and outcomes can be thought to be similar. For patients pre-
senting with severe disease, doxycycline-initiated treatment
results in greater costs (£2558, 95% CI £82 to £5198) and
poorer quality of life (0090 QALYs, 95% CI 022 to
0042), which together make this strategy appear a poor
investment (NMB £4361, 95% CI £8283 to £439) using
a willingness-to-pay criterion of < £20 000 per QALY gained.
Value of further research
An EVPI analysis was conducted to explore the value of reduc-
ing uncertainty about the cost-effectiveness of doxycycline- or
prednisolone-initiated therapy. EVPI analysis at the patient
Fig 2. Cost-effectiveness acceptability curve: doxycycline compared with prednisolone, base-case analysis.
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Fig 3. Cost-effectiveness plane: doxycycline compared with prednisolone, subgroup analysis. Cost per quality-adjusted life-year (QALY), £, 2015.
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level was conducted treating the two trial strata for index
lesion size as independent trials. The remaining value of
obtaining perfect information is low (Fig. 4). There remains
the greatest uncertainty about the management of patients
with mild-to-moderate disease. In 2012, 1018 patients were
hospitalized in England with a primary diagnosis of BP.22
Within the trial, 714% of patients presented with mild-to-
moderate disease based on the number of blisters present at
screening: if generalizable then the treatment of 727 patients
a year might be affected by greater certainty about treatment.
Assuming the findings affected care for 10 years the popula-
tion affected might number 7270, taking an EVPI of £242 per
patient. The population EVPI is £176 000, a fraction of the
average cost of a nationally recruiting multicentre clinical trial
(undiscounted costs).36 Taking into consideration the particu-
lar difficulties of conducting trials in this patient group, there
may not be scope to conduct a further definitive trial in
patients with mild-to-moderate disease.
Other end points
The three quality-of-life measures used in the BLISTER trial
are reported in Table 2. EQ-VAS, like EQ-5D, provides a 1-
year approximation of quality-adjusted survival for each treat-
ment group. EQ-VAS is scored 1–100; equivalent QALY scores
are obtained by dividing by 100, although EQ-VAS is not rec-
ommended for QALY estimation within trials, as values are
preference rated rather than societal. DLQI is scored 0–30; the
average score over the 1-year follow-up period is reported,
using the AUC between the three time points to calculate the
average. Being a disease-specific quality-of-life measure, the
DLQI is potentially more sensitive to change than a generic
measure; nonetheless, the changes correspond to an average of
1 point on a 30-point scale and are of uncertain clinical
importance.
Between-group differences for all three imputed quality-of-
life measures are shown in Table 2, included unadjusted,
baseline-score-adjusted and full-covariate-adjusted estimates.
Discussion
Patient-level data from the BLISTER trial provide the most
robust evidence to date on whether tetracycline-initiated ther-
apy is cost-effective as a treatment for patients with BP. The
trial addresses the comparative short-term effectiveness and
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Fig 4. Expected value of perfect information (EVPI): overall and subgroup analysis (£, 2015). QALY, quality-adjusted life-year.
Table 2 EQ-5D, EQ-VAS and DLQI estimates: doxycycline vs.
prednisolone
Area under the curve estimates
Mean
difference 95% CI
EQ-5D
Imputed, unadjusted 0037 (011 to 0039)
Imputed, baseline adjusted 0026 (0094 to 0042)
Imputed, covariate adjusted 0024 (0088 to 0041)
Mild/moderate disease 0001 (0074 to 0076)
Severe disease 0090 (022 to 0039)
EQ-VAS
Imputed, unadjusted 321 (313 to 954)
Imputed, baseline adjusted 056 (587 to 476)
Imputed, covariate adjusted 000 (514 to 515)
Mild/moderate disease 023 (548 to 593)
Severe disease 031 (1171 to 1110)
DLQI
Imputed, unadjusted 096 (003 to 189)
Imputed, baseline adjusted 117 (039 to 194)
Imputed, covariate adjusted 116 (038 to 195)
Mild/moderate disease 112 (026 to 198)
Severe disease 130 (044 to 304)
EQ-5D, EuroQoL-5D; EQ-VAS, EuroQoL visual analogue scale;
DLQI, Dermatology Life Quality Index.
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long-term safety of doxycycline and prednisolone. In the base-
case analysis (using multiple imputation), similar costs and
outcomes were found regardless of whether patients received
doxycycline-initiated therapy or prednisolone-initiated ther-
apy. The joint distribution of costs and QALYs nonetheless
suggests that doxycycline-initiated therapy may not be cost-
effective. However, this finding seems to have been driven by
the performance of the subgroup of patients with severe
disease.
For patients presenting with mild or moderate disease, the
economic and clinical findings align, and therefore treatment
decisions for those with mild or moderate disease should be
patient-led and informed by the different profiles of the two
drugs. Conversely, the clinical and economic findings for
patients with severe disease differ, and the economic analysis
provides a clear preference for prednisolone-initiated therapy
for patients presenting with severe disease. These findings
were robust to a range of sensitivity analyses using the com-
plete-case dataset, total rather than attributed costs, and differ-
ent levels of model adjustment.
The profile of EQ-5D scores encompasses short-term and
long-term patterns (Table S1). A small quality-of-life benefit
for prednisolone may occur in the first few months but disap-
pears by 6 months. Hence, although an extrapolation exercise
was originally planned as part of the economic analysis, with
modelling beyond 12 months, there was no rationale to pur-
sue this in the absence of significant differences in quality of
life or mortality.
This study has some limitations. BP is a rare disease affect-
ing mainly the very elderly, and so recruitment to trials in this
disease is a challenge. BLISTER recruited 253 patients from 54
U.K. and seven German hospitals over 45 years. The extent of
blistering was a stratification variable within the trial random-
ization, making the strata subgroups into nested randomized
controlled comparisons within the overall trial. Reflecting the
subgroup patient numbers, differentiation of cost-effectiveness
by extent of blistering would be strengthened by further evi-
dence before prioritizing prednisolone routinely for patients
with severe blistering.
BLISTER compared doxycycline-initiated with prednisolone-
initiated treatment rather than being an explanatory trial eval-
uating the pharmacological effects of these treatments. It is
possible that differences in cost and outcome may have been
diluted by patients switching study drugs.
Economic analysis, by modelling the bivariate distribution
of costs and QALYs, involves a range of assumptions. Judge-
ments are made about the base-case model, the estimation
method, adjustment for covariates, attribution of resource use
and unit costs applied, as well as the quality-of-life measure
used and societal weighting applied.
Incompleteness of the data contributing to the economic
analysis is a further potential weakness, a consequence of try-
ing to maintain data quality in a group of mainly elderly
patients with multiple morbidities across a high number of
recruiting sites and over a long period of time. Exploring the
consequence of imputation, the findings appear robust within
a range of sensitivity analyses. However, multiple imputations
inevitably requires strong assumptions about data being miss-
ing at random, which are only partially testable. Careful con-
sideration of modelling issues and use of sensitivity analyses,
exploring assumptions, provide some indication of the robust-
ness of the findings.
Patient-level data from the BLISTER trial provide the most
robust cost-effectiveness evidence to date comparing doxycy-
cline- and prednisolone-initiated treatment for patients with
BP. It should be noted that both drugs are inexpensive and in
routine use. The base-case analysis found similar, if imprecise,
costs and outcomes regardless of whether patients received
doxycycline-initiated therapy or prednisolone-initiated ther-
apy. However, post hoc subgroup analysis of patients with
severe blistering produced discrepant findings. On cost-effec-
tiveness grounds, there is a clear preference for prednisolone-
initiated therapy for those with severe disease. Discrepant find-
ings might be further understood by further trial-based evi-
dence, and also by qualitative work exploring patients’ views
on the trade-off between short-term blister control and long-
term safety.
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